Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Quilter sees double-digit growth in profits, AuMA

(Sharecast News) - Wealth management outfit Quilter has lifted its full-year dividend by 13% after a strong end to 2024, as the company reported double-digit profit growth and a big increase in assets under management and administration (AuMA). AuMA rose 12% to £119.4bn, with net inflows of £4.8bn, helped by what it called "supportive markets".

Chief executive Steven Levin said 2024 was an "excellent year in terms of net inflows, revenue momentum, cost discipline and profit growth".

Revenues were up 7% at £670m, reflecting higher management fee revenue on higher asset levels combined with increased investment revenue generated on shareholder funds.

Adjusted pre-tax profit was 17% higher at £196m, helped by a two-percentage point increase in the operating margin to 29%.

The bottom line was also helped by Quilter's "simplification programme" which delivered £35m of the targeted £50m of savings, with the remainder expected to be achieved by the end of this year.

The company proposed a full-year dividend of 5.9p per share, up from 5.2p in 2023.

Meanwhile, Quilter's so-called "skilled person review", which was kicked off last year after concerns raised by the FCA, is still ongoing but is expected to be completed during the second quarter. The company has now put aside £76m as a "customer remediation exercise provision" to cover potential redress for clients that did not receive ongoing advice.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.